Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesInitiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure
Journal of Acquired Immune Deficiency Syndromes, 07/16/09
Uy J et al. - Patients failing HAART that was initiated at <350 CD4 cells per cubic millimeter had higher frequencies of resistance mutations to the classes of antiretrovirals to which they had been exposed than failing patients who initiated at >=350 CD4 cells per cubic millimeter. Initiating HAART at higher CD4 cell counts may decrease the risk of developing treatment-limiting antiretroviral resistance.
Related Articles
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
Relevance Score: 95%
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Relevance Score: 95%
Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09
Relevance Score: 94%
Sperm May Play Leading Role In Spreading HIV
ScienceDaily, 10/27/09
Relevance Score: 94%
Female sex work and HIV risks in Croatia
AIDS Care, 10/29/09
Relevance Score: 93%
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor